<DOC>
	<DOCNO>NCT01582347</DOCNO>
	<brief_summary>This study design determine opioid dependent subject already receive Subutex and/or Suboxone transfer RBP-6300 . Upon complete study , subject continue pre-study prescribed dosage Subutex and/or Suboxone</brief_summary>
	<brief_title>Transfer Subjects From Subutex/Suboxone RBP-6300</brief_title>
	<detailed_description>During open-label Run-In Period ( study day -7 -1 ) , participant receive Subutex®/Suboxone® one three dose level , depend dose level subject entry study : 8 mg/day , 16 mg/day , 24 mg/day . During 7-day , active drug-controlled , double-blind Transfer Period ( study day 1-7 ) , participant randomize either Subutex®/Suboxone® RBP-6300 active drug dosing level equivalent level Run-In Period plus placebo matching drug . This follow 3-day single-blind Subutex®/Suboxone® Transition Period participant receive dose give Run-In Period .</detailed_description>
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<mesh_term>Buprenorphine , Naloxone Drug Combination</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>Be Male nonpregnant , nonlactating female Be least 18 year age Meet Diagnostic Statistical Manual Mental Disorders , DSMIVTR ( Diagnostic Statistical ManualIVTEXT REVISION ) criteria opioid dependence screen Be stable dose 8 , 16 , 24mg/day 30 day prior screen Female subject childbearing potential must negative urine test prior enrollment study Have participate experimental drug device study within last 60 day If female , breast feeding lactate Have medical condition opinion physician investigator would preclude subject complete study Have clinically significant abnormal finding ( opinion investigator )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Opioid dependence</keyword>
</DOC>